How should we interpret the U.S. stock market performance on May 11, 2026?

U.S. nonfarm payrolls for April added 115,000 jobs—far exceeding expectations—driven by robust corporate earnings and companies’ effective mitigation of supply-chain disruptions stemming from the Iran conflict. The unemployment rate held steady at 4.3%, in line with economists’ forecasts. Policy shifts across trade, immigration, and taxation continue to challenge businesses, yet most firms have refrained from large-scale layoffs. Earlier this week, data from the Department of Labor and ADP—a human resources firm—indicated stabilization in the labor market. Strong hiring in healthcare and social assistance further bolstered overall employment figures. U.S. equities are trading near or at record highs, boosting CEO confidence. However, the full impact of the conflict with Iran—and its associated energy price surge—has yet to manifest in labor-market data. The Philadelphia Semiconductor Index surged over 5% to a new high. ASML rose nearly 5%, AMD jumped over 11%, and both hit record highs. Intel soared nearly 14% to a new high; insiders revealed that Apple and Intel have reached a preliminary agreement under which Intel will manufacture certain chips for Apple devices. The Trump administration holds a 10% stake in Intel, and both President Trump and the U.S. Secretary of Commerce reportedly engaged in repeated advocacy and matchmaking efforts to facilitate this collaboration. Memory chip stocks continued their rally: SanDisk surged over 16%—up 558% year-to-date; Micron Technology rose over 15%—up more than 160% year-to-date; both hit record highs. Western Digital gained over 3%, and Seagate Technology rose over 2%. Rocket Lab USA, Inc. surged over 34% to a new high. Its Q1 revenue surpassed $200 million for the first time, and the company announced it had secured its largest-ever launch contract as well as an order under the Trump administration’s ‘Golden Dome’ missile defense program—demonstrating rapid expansion of its commercial space portfolio. Moderna, Inc. rose 12%. It reported positive Phase I clinical data for its mRNA-based hantavirus vaccine, showing good tolerability and strong immune responses across all dose levels. CoreWeave, Inc. plunged over 11%. Its Q1 revenue reached $2.078 billion, up 112% year-on-year and above market expectations—but net losses widened sharply to $740 million, and adjusted net losses also expanded significantly.

Inari’s FY26 results met expectations—but the real test lies in recovery during FY27–28.

Yet 'meeting expectations' does not imply growth—it reflects the market’s prior recognition of the underlying cause of decline: low RF business loading. More telling is the quarter-on-quarter trend: FY26 Q4 revenue stood at RM288.9 million, up 9% sequentially; core PATAMI was RM47 million, up 72% sequentially; and core margin rebounded from 10% in Q3 to 16%. Citigroup attributes this improvement to recovering RF volumes and stronger optoelectronics contributions. [880559 p.1][880559 p.3] This suggests the worst may be over—but falls short of confirming a robust recovery. FY26 revenue, profit, and quarterly trends. Source: Citigroup Research, company filings; excerpt from page 3 of original report. Breaking down recovery into three product-level logics: First, RF: Inari provides RF chip packaging and testing services, and its profitability is highly sensitive to smartphone cycles and customer loading volumes. The core issue in FY26 was not capacity loss—but insufficient volume. If the next smartphone cycle restores loading, fixed-cost absorption would amplify profit elasticity beyond revenue elasticity. The report characterizes RF as the medium-term earnings floor—not a new high-growth narrative. [880559 p.2] Second, optoelectronics: This segment addresses high-speed optical interconnect demand in AI infrastructure—the part of Inari’s business investors assign longer-duration valuation potential. Citigroup judges the long-term outlook for optoelectronics strengthening and expects its contribution to rise further—but this remains a broker’s view, not yet reflected in realized revenue. What truly matters is new-product ramp-up, yield rates, customer concentration, and gross margins—not vague references to 'strong AI demand'. Third, datacom: This logic stems from global data-center capital expenditures—but the path from capex to Inari orders involves multiple intermediaries: customer qualification, share competition, and delivery timing. In other words, RF sets the floor for recovery; optoelectronics and datacom define its ceiling—these three lines must not be conflated into a single concept. Quarterly inflection points require annual base validation: Q4 FY26’s sequential recovery is significant—but cannot be directly annualized into FY27 growth. With Q4 revenue at RM288.9 million, even a simple multiplication by four yields only a rough observational benchmark—not management guidance. Similarly, core PATAMI of RM47 million reflects the combined impact of that quarter’s product mix, expenses, and exchange rates. [880559 p.1][880559 p.3] A more prudent interpretation treats Q4 as a starting point: rising RF loading first improves capacity absorption; growing optoelectronics contribution then lifts product-mix quality. Only if both trends persist can annual profits approach Citigroup’s forecast. Also note the base effect: FY26 core PATAMI declined 26% year-on-year, so FY27E’s projected 46.9% growth reflects both low-base effects and genuine operational improvement. [880559 p.1] What the market truly needs is not a one-off profit jump—but consistent, multi-quarter alignment across revenue, core margin, and cash conversion. If margin expansion stems solely from temporary cost reductions—or if revenue rebounds while receivables and inventory burdens worsen—recovery quality remains questionable. Profit curves are steeper—and more fragile—than narratives.

Ecovyst Inc. 2Q 2026: Revenue $249.96M, EPS $0.07— 10-Q Summary

Aug 6, 2026

Ecovyst Inc. reported Q2 2026 revenue of $249.96 million, up 42% year-over-year, driven by higher sulfuric acid prices and volumes following the Calabrian acquisition. Diluted EPS rose to $0.07 amid improved refinery utilization and strategic contract protections.

TradingView

Ecovyst Inc. 2Q 2026: Revenue $249.96M, EPS $0.07— 10-Q Summary

TradingView

2026-04-20

Ecovyst to Host First Quarter 2026 Earnings Conference Call and Webcast

2026-04-29

Ecovyst to Hold First-Quarter 2026 Earnings Call on May 5

2026-05-04

Ecovyst earnings up next: Can refining demand sustain momentum?

2026-05-05

Ecovyst Posts Strong Q1 2026 Results and Higher 2026 Outlook